Academic Journal
P694 COVID-19 vaccination rate and willingness of an additional dose among inflammatory bowel disease patients receiving biologic therapy
| العنوان: | P694 COVID-19 vaccination rate and willingness of an additional dose among inflammatory bowel disease patients receiving biologic therapy |
|---|---|
| المؤلفون: | Ramos Lopez, L, Carrillo-Palau, M, Alonso-Abreu, I, Reygosa, C, Hernández-Buylla, N, Amaral, C, Hernández, A, Benítez-Zafra, F, Pérez-González, F, Quintana-Díaz, H, Hernández-Guerra, M |
| المصدر: | Journal of Crohn's and Colitis ; volume 16, issue Supplement_1, page i592-i593 ; ISSN 1873-9946 1876-4479 |
| بيانات النشر: | Oxford University Press (OUP) |
| سنة النشر: | 2022 |
| الوصف: | Background Vaccination against COVID19 prevents its severe forms and associated mortality and offers a promising action to control this pandemic. In Spain, by October 2021, 87.9% of the target population, including IBD patients had received the complete vaccination regimen. In September 2021, an additional dose of vaccine was approved in patients with immunosuppression including IBD patients on biologic agents. We evaluated the vaccination rate and additional dose willingness in this group of-at risk patients. Methods A single-center, cross-sectional study was performed among IBD patients on biologic agents and elegibles for an additional dose of COVID19 vaccine between 19th October and 12th November 2021. Patients were identified by the list provided by the Pharmacy service. IBD clinical characteristics and type of vaccine and date of administration were checked in medical records. Acceptance and adverse effects of vaccination were evaluated after telephone or face-to-face survey in these IBD patients. Results Out of a total of 344 patients, 269 patients (46.1% male; mean age 47±16 years; crohn′s disease n=198/ ulcerative colitis n=66/ indeterminate colitis n=5) received at least one vaccine dose and were included. The patients were on Infliximab (40.9%), Ustekinumab (29.7%), Adalimumab (20%), and Vedolizumab (8.9%). Co-treatment with immunosuppressors was used in 73.2% of patients. Only 15 (5.6%) patients refused the COVID19 vaccine: 26.7% for fear of vaccine`s adverse effects, 33.3% for doubts about a “new-design” vaccine and 40% for conviction (COVID19 pandemic denial). 46.7% of the cases would not change their opinion, but 33.3% would re-consider after discussing with their doctor and/or receiving information on the adverse effects of the vaccine. Previous to the additional dose, COVID19 vaccination was present in 94.4% of patients (n=254) (complete regimen using Pfizer 63%,Astra-Zeneca 15.4%, Moderna 12.2% and Janssen in 9.4% of patients, respectively). 42.7% of patients personally requested the ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1093/ecco-jcc/jjab232.815 |
| الاتاحة: | https://doi.org/10.1093/ecco-jcc/jjab232.815 https://academic.oup.com/ecco-jcc/article-pdf/16/Supplement_1/i592/42252774/jjab232.815.pdf |
| Rights: | https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model |
| رقم الانضمام: | edsbas.6B8F4393 |
| قاعدة البيانات: | BASE |
| ResultId |
1 |
|---|---|
| Header |
edsbas BASE edsbas.6B8F4393 938 3 Academic Journal academicJournal 937.599182128906 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.6B8F4393&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://doi.org/10.1093/ecco-jcc/jjab232.815# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => P694 COVID-19 vaccination rate and willingness of an additional dose among inflammatory bowel disease patients receiving biologic therapy
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Ramos+Lopez%2C+L%22">Ramos Lopez, L</searchLink><br /><searchLink fieldCode="AR" term="%22Carrillo-Palau%2C+M%22">Carrillo-Palau, M</searchLink><br /><searchLink fieldCode="AR" term="%22Alonso-Abreu%2C+I%22">Alonso-Abreu, I</searchLink><br /><searchLink fieldCode="AR" term="%22Reygosa%2C+C%22">Reygosa, C</searchLink><br /><searchLink fieldCode="AR" term="%22Hernández-Buylla%2C+N%22">Hernández-Buylla, N</searchLink><br /><searchLink fieldCode="AR" term="%22Amaral%2C+C%22">Amaral, C</searchLink><br /><searchLink fieldCode="AR" term="%22Hernández%2C+A%22">Hernández, A</searchLink><br /><searchLink fieldCode="AR" term="%22Benítez-Zafra%2C+F%22">Benítez-Zafra, F</searchLink><br /><searchLink fieldCode="AR" term="%22Pérez-González%2C+F%22">Pérez-González, F</searchLink><br /><searchLink fieldCode="AR" term="%22Quintana-Díaz%2C+H%22">Quintana-Díaz, H</searchLink><br /><searchLink fieldCode="AR" term="%22Hernández-Guerra%2C+M%22">Hernández-Guerra, M</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Journal of Crohn's and Colitis ; volume 16, issue Supplement_1, page i592-i593 ; ISSN 1873-9946 1876-4479 ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Oxford University Press (OUP) ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2022 ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Background Vaccination against COVID19 prevents its severe forms and associated mortality and offers a promising action to control this pandemic. In Spain, by October 2021, 87.9% of the target population, including IBD patients had received the complete vaccination regimen. In September 2021, an additional dose of vaccine was approved in patients with immunosuppression including IBD patients on biologic agents. We evaluated the vaccination rate and additional dose willingness in this group of-at risk patients. Methods A single-center, cross-sectional study was performed among IBD patients on biologic agents and elegibles for an additional dose of COVID19 vaccine between 19th October and 12th November 2021. Patients were identified by the list provided by the Pharmacy service. IBD clinical characteristics and type of vaccine and date of administration were checked in medical records. Acceptance and adverse effects of vaccination were evaluated after telephone or face-to-face survey in these IBD patients. Results Out of a total of 344 patients, 269 patients (46.1% male; mean age 47±16 years; crohn′s disease n=198/ ulcerative colitis n=66/ indeterminate colitis n=5) received at least one vaccine dose and were included. The patients were on Infliximab (40.9%), Ustekinumab (29.7%), Adalimumab (20%), and Vedolizumab (8.9%). Co-treatment with immunosuppressors was used in 73.2% of patients. Only 15 (5.6%) patients refused the COVID19 vaccine: 26.7% for fear of vaccine`s adverse effects, 33.3% for doubts about a “new-design” vaccine and 40% for conviction (COVID19 pandemic denial). 46.7% of the cases would not change their opinion, but 33.3% would re-consider after discussing with their doctor and/or receiving information on the adverse effects of the vaccine. Previous to the additional dose, COVID19 vaccination was present in 94.4% of patients (n=254) (complete regimen using Pfizer 63%,Astra-Zeneca 15.4%, Moderna 12.2% and Janssen in 9.4% of patients, respectively). 42.7% of patients personally requested the ... ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article in journal/newspaper ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1093/ecco-jcc/jjab232.815 ) Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => https://doi.org/10.1093/ecco-jcc/jjab232.815<br />https://academic.oup.com/ecco-jcc/article-pdf/16/Supplement_1/i592/42252774/jjab232.815.pdf ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.6B8F4393 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1093/ecco-jcc/jjab232.815
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => P694 COVID-19 vaccination rate and willingness of an additional dose among inflammatory bowel disease patients receiving biologic therapy
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ramos Lopez, L
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Carrillo-Palau, M
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Alonso-Abreu, I
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Reygosa, C
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Hernández-Buylla, N
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Amaral, C
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Hernández, A
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Benítez-Zafra, F
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Pérez-González, F
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Quintana-Díaz, H
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Hernández-Guerra, M
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Type] => published
[Y] => 2022
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-locals
[Value] => edsbas
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsbas.oa
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Journal of Crohn's and Colitis ; volume 16, issue Supplement_1, page i592-i593 ; ISSN 1873-9946 1876-4479
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |